Prochlorperazine (Compazine)

Prochlorperazine, marketed under the brand name Compazine, is a phenothiazine-class medication with potent antiemetic and antivertigo properties that is occasionally used in rabbit medicine for the management of severe vestibular symptoms. This medication represents a more intensive treatment option compared to first-line antihistamines like meclizine, typically reserved for cases where vestibular symptoms are severe enough to significantly impact the rabbit's ability to eat and function. Prochlorperazine's stronger pharmacological action makes it valuable for acute vestibular crises but requires careful veterinary supervision.

The mechanism of action of prochlorperazine involves blocking dopamine receptors in the chemoreceptor trigger zone (CTZ) of the brain, which is the primary center responsible for triggering nausea and the sensation of motion sickness. Additionally, prochlorperazine has antihistamine and anticholinergic properties that contribute to its antivertigo effects. This multi-receptor activity provides powerful symptom relief for rabbits experiencing severe disorientation, though it also accounts for the medication's broader range of potential side effects compared to simpler antihistamines.

Prochlorperazine is available in tablet form for human use and as injectable solutions, though most rabbit applications involve compounded oral formulations prepared by veterinary pharmacies to allow accurate dosing. The medication can be administered once to twice daily depending on symptom severity, with injectable forms occasionally used by veterinarians for initial treatment of acute vestibular crises. Due to its prescription status and the need for careful dosing, prochlorperazine is not appropriate for owner administration without explicit veterinary guidance and oversight.

The use of prochlorperazine in rabbits requires careful consideration of risks and benefits by a rabbit-savvy veterinarian. While the medication can provide dramatic relief for severely affected rabbits, the phenothiazine class carries potential for significant side effects including excessive sedation, blood pressure changes, and effects on temperature regulation. For most vestibular cases, milder antihistamines such as meclizine are preferred as first-line treatment, with prochlorperazine reserved for cases that fail to respond adequately or where symptoms are immediately threatening the rabbit's wellbeing by preventing eating.

The primary indication for prochlorperazine in rabbits is severe vestibular disease with significant nausea affecting the rabbit's ability to eat and maintain nutrition. Vestibular dysfunction from any cause can produce intense disorientation and nausea that makes eating impossible for affected rabbits. While mild to moderate cases often respond to meclizine or other antihistamines, severe cases may require the more potent antiemetic action of prochlorperazine to break the cycle of nausea and anorexia that can quickly lead to dangerous gastrointestinal stasis.

Acute vestibular crisis represents the scenario where prochlorperazine is most commonly considered. When a rabbit suddenly develops severe head tilt with continuous rolling, complete inability to maintain balance, and total food refusal, immediate intervention is needed to stabilize the patient. Prochlorperazine's potent antiemetic effect can provide rapid relief in these crisis situations, allowing the rabbit to regain enough comfort to accept food and water while definitive diagnosis and treatment of the underlying cause proceeds.

Head tilt associated with E. cuniculi infection is a common underlying cause of vestibular symptoms that may require prochlorperazine support. While fenbendazole addresses the parasitic infection itself, the vestibular symptoms may be severe during the initial phase of illness. If meclizine provides insufficient relief, prochlorperazine may be considered as part of the supportive care regimen. The medication does not treat E. cuniculi itself and must be used alongside appropriate antiparasitic therapy.

Inner ear infections (otitis interna) causing vestibular symptoms represent another scenario where prochlorperazine may be indicated. Bacterial infections of the inner ear can cause severe vertigo and nausea while the infection is being treated with antibiotics. The timeline for antibiotic effectiveness may span days to weeks, during which symptomatic relief with antiemetics helps maintain the rabbit's nutritional status and comfort. Prochlorperazine provides stronger symptom control than meclizine for severely affected individuals.

Prochlorperazine may occasionally be considered for other causes of severe nausea in rabbits beyond vestibular disease, though such uses are less common. Any condition causing persistent anorexia due to nausea might potentially benefit from antiemetic therapy, though identifying and treating the underlying cause remains the priority. Your rabbit-savvy veterinarian will determine whether prochlorperazine is appropriate based on the specific clinical situation and whether milder interventions have been adequate.

Dosing of prochlorperazine in rabbits requires careful veterinary calculation, as this medication has a narrower therapeutic window than some other antiemetics and rabbit doses differ substantially from human doses. General guidelines suggest 0.1 to 0.5 mg/kg orally or by injection, typically once to twice daily, but the specific dose for your rabbit must be determined by your rabbit-savvy veterinarian based on your pet's weight, severity of symptoms, and overall condition. The relatively potent nature of this medication means that accurate dosing is particularly important.

Weight-based dosing calculation is essential given prochlorperazine's potency and the small size of rabbit patients relative to humans. Your rabbit's weight should be accurately determined using a gram scale, as estimation can lead to significant dosing errors. The veterinarian will calculate the precise dose needed, which for most rabbits represents only a tiny fraction of standard human tablet strengths. Compounded liquid formulations are frequently prescribed to allow accurate measurement of these small doses.

Treatment duration with prochlorperazine is typically shorter than with milder antiemetics, reflecting its use for acute symptom control rather than extended maintenance therapy. Most rabbits receive prochlorperazine for several days during the acute phase of vestibular crisis, with transition to milder medications like meclizine once symptoms become more manageable. Prolonged use of phenothiazines is generally avoided due to cumulative side effect risks. Your veterinarian will advise on appropriate duration based on your rabbit's response.

Administration of prochlorperazine tablets requires crushing and accurate portioning, which can be challenging given the small doses needed for rabbits. Compounded oral suspensions prepared by veterinary pharmacies simplify administration significantly and allow more accurate dosing using calibrated oral syringes. The medication can be given directly into the mouth or mixed with a small amount of palatable food if the rabbit is eating. Injectable prochlorperazine is typically administered by the veterinarian during initial treatment and is not generally dispensed for home use.

If a dose is missed, contact your veterinarian for guidance rather than automatically administering the missed dose. Because prochlorperazine is typically used for acute symptom control with a defined short-term protocol, missed doses may affect the treatment plan differently than with maintenance medications. Never double the dose without explicit veterinary instruction. If multiple doses are missed, your veterinarian may need to reassess the treatment approach.

Discontinuation of prochlorperazine is typically done under veterinary guidance as symptoms improve. The goal is to transition to milder antiemetic support or discontinue antiemetic therapy entirely as the underlying condition resolves. Abrupt discontinuation is generally acceptable given the short treatment courses typically used, though some veterinarians may prefer a brief taper to assess symptom control before stopping completely.

Prochlorperazine carries a broader side effect profile than antihistamine-class antiemetics, reflecting its more potent pharmacological action through dopamine receptor blockade. While many rabbits tolerate short courses of prochlorperazine without significant problems, awareness of potential adverse effects allows for appropriate monitoring and early intervention if needed. The decision to use prochlorperazine involves weighing these risks against the benefits of symptom relief in severely affected patients.

Sedation is the most common side effect of prochlorperazine in rabbits and can range from mild drowsiness to profound lethargy depending on the dose and individual sensitivity. Some degree of sedation may actually be beneficial in severely disoriented vestibular patients who are prone to rolling and self-injury, as it reduces dangerous activity during the acute phase. However, excessive sedation that prevents eating or drinking is counterproductive. If your rabbit becomes too sedated to eat, contact your veterinarian about dose adjustment.

Hypotension (low blood pressure) can occur with phenothiazine medications including prochlorperazine. Signs that might indicate blood pressure effects in rabbits include weakness, pale gums or ears, cold extremities, or collapse. These effects are more likely with injectable administration or higher doses. Rabbits receiving prochlorperazine should be monitored for signs of cardiovascular effects, particularly during initial treatment. If concerning signs develop, veterinary evaluation is needed promptly.

Temperature regulation can be affected by phenothiazine medications, making rabbits more susceptible to environmental temperature extremes. Rabbits receiving prochlorperazine should be kept in a comfortable, temperature-controlled environment and monitored for signs of being too cold or too warm. This effect is typically mild at therapeutic doses but warrants awareness, particularly in rabbits housed in areas with temperature fluctuation.

Serious adverse effects from prochlorperazine, while uncommon at appropriate doses, include extrapyramidal effects (involuntary movement abnormalities), severe cardiovascular depression, or prolonged excessive sedation. Signs requiring immediate veterinary attention include rigid muscle tremors, severe weakness or collapse, extremely slow or rapid heart rate, respiratory difficulty, or inability to rouse the rabbit. These serious effects are rare but represent emergencies requiring prompt intervention.

Known hypersensitivity to prochlorperazine or other phenothiazine medications represents an absolute contraindication to use. Rabbits that have previously shown adverse reactions to phenothiazines should not receive prochlorperazine. Cross-reactivity between different phenothiazine medications is common, so history of reaction to any drug in this class warrants avoidance. If the history is unclear, careful monitoring during initial doses is essential.

Significant cardiovascular disease may contraindicate prochlorperazine use due to the medication's potential effects on blood pressure and heart function. Rabbits with known heart conditions, severe dehydration leading to cardiovascular compromise, or those in shock should not receive prochlorperazine without careful veterinary assessment of risks versus benefits. In these cases, alternative approaches to nausea management may be more appropriate.

Liver dysfunction represents a significant concern for prochlorperazine use, as the medication is metabolized hepatically. Rabbits with known liver disease, elevated liver enzymes, or other indicators of hepatic compromise may process prochlorperazine more slowly, leading to accumulation and increased risk of adverse effects. Alternative antiemetics may be safer in rabbits with liver impairment, or doses may need significant reduction under careful veterinary monitoring.

Pregnancy and nursing represent contraindications for prochlorperazine in most circumstances. Phenothiazine medications can cross the placenta and may affect developing fetuses. The medication also appears in milk and could affect nursing offspring. Unless vestibular symptoms are life-threatening in a pregnant or nursing doe, alternative treatments should be sought. If prochlorperazine is deemed absolutely necessary, the risks must be carefully discussed with your veterinarian.

Concurrent use of other medications that cause sedation or cardiovascular depression may contraindicate prochlorperazine use or require significant dose adjustment. The additive effects of multiple sedating or hypotensive medications can produce dangerous cumulative depression. A complete medication history, including any recent sedatives or anesthetics, should be reviewed before prochlorperazine administration. Very young kits or severely debilitated rabbits may also be inappropriate candidates due to limited physiological reserve.

Prochlorperazine has numerous potential drug interactions due to its effects on multiple neurotransmitter systems and cardiovascular function. Comprehensive disclosure of all medications, supplements, and treatments your rabbit is receiving is essential before prochlorperazine is prescribed. Your veterinarian will evaluate potential interactions and adjust the treatment plan accordingly to ensure safety while maintaining therapeutic benefit.

Concurrent use with other sedating medications produces additive central nervous system depression that can be dangerous. This includes other phenothiazines, antihistamines like meclizine, opioid pain medications, and sedatives. While combination therapy may occasionally be appropriate under careful veterinary supervision, doses typically need reduction when multiple sedating drugs are used together. If your rabbit is receiving any medication that causes drowsiness, this must be disclosed before prochlorperazine administration.

Medications that lower blood pressure can interact dangerously with prochlorperazine's hypotensive effects. Concurrent use of other hypotensive agents, including certain cardiac medications or vasodilators, may produce additive blood pressure reduction leading to cardiovascular compromise. Rabbits receiving any cardiovascular medications should have prochlorperazine used only with extreme caution and careful monitoring, if at all.

Anticholinergic medications interact with prochlorperazine's own anticholinergic properties to produce additive effects. This can result in excessive reduction in gut motility, urinary retention, or other anticholinergic effects. Medications with anticholinergic properties that might be used in rabbits include certain GI medications. When combination is necessary, close monitoring for anticholinergic toxicity is warranted.

Prochlorperazine can interact with fenbendazole and other medications commonly used in E. cuniculi treatment primarily through additive effects on the rabbit's overall physiological state rather than direct pharmacokinetic interactions. A rabbit receiving fenbendazole for E. cuniculi and prochlorperazine for symptomatic relief needs monitoring for cumulative effects on appetite and activity. There are no known direct interactions that would preclude this combination when clinically indicated, but overall patient status must be considered.

Several critical precautions govern safe prochlorperazine use in rabbit patients. First and foremost, this medication should only be used when milder antiemetics have proven insufficient and vestibular symptoms are significantly impacting the rabbit's ability to eat and maintain health. Prochlorperazine is not appropriate as a first-line treatment for mild to moderate vestibular disease, where meclizine or similar antihistamines typically provide adequate relief with better safety margins.

Proper veterinary diagnosis before initiating prochlorperazine treatment is essential. The medication provides symptomatic relief but does not address underlying causes of vestibular disease such as E. cuniculi infection, ear infections, or other conditions. Using prochlorperazine to mask symptoms without pursuing definitive diagnosis can allow serious conditions to progress while creating false impressions of improvement. Treatment of underlying causes must proceed alongside symptomatic management.

Accurate dosing is particularly critical with prochlorperazine given its potency and potential for adverse effects. Your rabbit's weight must be precisely determined, and doses must be carefully calculated by your veterinarian. Home dose estimation or guessing at appropriate amounts is dangerous with this medication. If compounded formulations are prescribed, use only calibrated syringes for administration and follow dosing instructions exactly.

Monitoring during prochlorperazine treatment should be more intensive than with milder medications. Observe your rabbit closely for signs of excessive sedation, weakness, changes in breathing pattern, or cold extremities that might indicate cardiovascular effects. Appetite and fecal output should be tracked daily, as the goal of treatment is to improve eating, and the medication should not be continued if it is not achieving this purpose. Any concerning changes warrant veterinary contact.

Environmental considerations during prochlorperazine treatment include maintaining a comfortable temperature and providing safe, padded housing for severely affected vestibular patients. The medication's effects on temperature regulation and sedation may make rabbits less able to thermoregulate or protect themselves from injury. Keep treated rabbits in quiet, climate-controlled areas and ensure they cannot fall or roll onto hard surfaces. Supervised time with the rabbit helps catch problems early.

Storage requirements for prochlorperazine vary by formulation but generally require protection from light, heat, and moisture to maintain stability. Commercial tablets should be stored in their original containers at controlled room temperature, typically between 68°F and 77°F (20°C to 25°C). The medication is light-sensitive, so storage in a dark location or opaque container is recommended. Avoid bathroom medicine cabinets where humidity fluctuates significantly.

Compounded oral formulations of prochlorperazine, which are commonly prescribed for rabbit use due to the need for accurate small doses, typically require refrigeration and have shorter stability periods than commercial tablets. Follow the specific storage instructions provided by the compounding pharmacy, as formulations vary. Most compounded liquids should be kept refrigerated at 36°F to 46°F (2°C to 8°C) and used within the beyond-use date specified, typically 30 to 90 days after preparation.

Safety considerations for prochlorperazine storage are particularly important due to the medication's potency. Keep all prochlorperazine formulations securely stored out of reach of children and away from areas accessible to rabbits or other pets. Accidental ingestion of prochlorperazine can cause significant sedation and other effects. A locked medicine cabinet or secure container in a room the rabbit cannot access provides appropriate security.

Handling precautions may apply for some prochlorperazine formulations. The medication can be absorbed through skin in liquid form, and some individuals are sensitive to phenothiazine compounds. While casual exposure during normal pet medication administration is unlikely to cause problems, some caregivers prefer to wear gloves when handling compounded liquid formulations, particularly for repeated administrations. Wash hands after handling the medication.

Disposal of unused prochlorperazine requires appropriate handling as a prescription medication. Many communities have drug take-back programs that accept unused prescriptions. If no take-back program is available, the FDA recommends mixing medications with undesirable substances like used coffee grounds or kitty litter and placing in sealed containers for household trash. Do not flush prochlorperazine or pour it down drains. Compounded formulations should be disposed of according to the pharmacy's instructions.

Prochlorperazine can be used in rabbits of all breeds when clinically indicated, without specific breed contraindications or known breed-specific sensitivities to the medication. However, the practical aspects of dosing, administration, and monitoring may vary based on breed-related size differences. Because prochlorperazine has a narrower safety margin than some other medications, accurate breed-appropriate dosing is particularly important.

Dwarf breeds including Netherland Dwarfs, Holland Lops, Polish rabbits, and similar small varieties require extremely careful dosing due to their small body size. These rabbits may weigh as little as 1-2 kg, meaning their prochlorperazine doses are proportionally tiny. Compounded liquid formulations are essentially mandatory for dwarf breeds to allow accurate measurement of the small volumes needed. Even minor dosing errors can represent significant percentage variations in such small patients, potentially leading to underdosing or dangerous overdosing.

Giant breeds such as Flemish Giants, Continental Giants, and Checkered Giants require larger total doses based on their greater body weight. While the dose per kilogram remains similar, giant breeds may require amounts approaching those used in small dogs. These larger doses may affect side effect risk and duration, requiring appropriate monitoring. Despite their size, giant breed rabbits remain sensitive to phenothiazines and do not have substantially different safety margins on a per-weight basis.

Lop-eared breeds warrant special consideration in the context of vestibular disease treatment because their ear anatomy predisposes them to inner ear infections (otitis), a common cause of vestibular symptoms. Lop rabbits presenting with severe vestibular disease may have bacterial ear infections requiring antibiotic treatment alongside symptomatic prochlorperazine therapy. The underlying ear pathology must be addressed; prochlorperazine provides symptom relief but does not treat infections.

Age-related factors intersect with breed when considering prochlorperazine use. Young rabbits of any breed have immature metabolic systems that may process medications differently, potentially making them more sensitive to phenothiazine effects. Geriatric rabbits, regardless of breed, may have reduced organ function affecting drug metabolism and may be more susceptible to sedation and cardiovascular effects. Extra caution with dosing and more intensive monitoring is appropriate for very young or elderly rabbits of any breed.

Several medications serve related or alternative roles in managing vestibular symptoms and nausea in rabbits. Understanding these options provides context for treatment decisions when prochlorperazine is being considered. Your rabbit-savvy veterinarian will select the most appropriate medication based on symptom severity, underlying diagnosis, and your rabbit's individual response.

Meclizine (Antivert/Bonine) is typically the first-line antiemetic for vestibular symptoms in rabbits and represents a safer alternative to prochlorperazine for mild to moderate cases. This antihistamine provides effective relief for many vestibular patients with a more favorable side effect profile. Prochlorperazine is generally reserved for cases where meclizine provides insufficient symptom control, or for acute crisis situations requiring more potent intervention. Many rabbits are successfully managed with meclizine alone.

Dimenhydrinate (Dramamine) is another antihistamine antiemetic that serves as an alternative to meclizine for vestibular symptom management. Like meclizine, dimenhydrinate is safer than phenothiazines and appropriate for less severe cases. The choice between meclizine and dimenhydrinate often comes down to veterinary preference and individual patient response. Both represent preferable options to prochlorperazine for routine vestibular support.

Metoclopramide (Reglan) is a different class of antiemetic that primarily works by enhancing gastric motility and has some central antiemetic effects. While not typically used specifically for vestibular symptoms, metoclopramide may be helpful when nausea is contributing to gastric stasis, as it addresses both nausea and gut motility simultaneously. This medication is often part of GI stasis treatment protocols and may complement vestibular-focused antiemetics.

Fenbendazole (Panacur) is not an antiemetic but is essential to mention because E. cuniculi infection is a leading cause of vestibular disease requiring antiemetic support. Fenbendazole treats the underlying parasitic infection while prochlorperazine or other antiemetics manage symptoms. Any rabbit receiving prochlorperazine for E. cuniculi-related vestibular disease must also receive appropriate fenbendazole therapy. Supportive care measures including assisted feeding with Critical Care, subcutaneous fluids for hydration, and probiotics work alongside antiemetics to optimize outcomes for vestibular disease patients.